ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLP Scancell Holdings Plc

9.60
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.60 9.40 9.80 9.60 9.60 9.60 111,483 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.44 89.07M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.60p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £89.07 million. Scancell has a price to earnings ratio (PE ratio) of -7.44.

Scancell Share Discussion Threads

Showing 62651 to 62674 of 65850 messages
Chat Pages: Latest  2514  2513  2512  2511  2510  2509  2508  2507  2506  2505  2504  2503  Older
DateSubjectAuthorDiscuss
16/8/2023
12:27
BARCELONA, 16 - 19 OCTOBER 2023


Oct 19 11:00

Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination
Cancer & Therapeutic Vaccines

Lindy Durrant,Joint Chief Executive Officer and Cso,Scancell Ltd

marcusl2
16/8/2023
11:07
FWIW I think the SCIB update will be a material upside surprise. We've all defocused on it, given the protracted trial, but my read of company actions is they are teeing up for a positive outcome.
markingtime
16/8/2023
09:44
Lozan, you are even more stupid than I originally thought. They are all your comments and anyone can look at your posts to see them. P.S. I have them saved. e.g.

the real lozan - 30 Jun 2016 - 17:30:42 - 17492 of 40759 FRANCE: A Second Home or a Maison to retire to. - FROG
In my own case, I had no so-called

Maybe better that you leave this and we agree to keep it pleasant and on topic about Scancell.

marcusl2
16/8/2023
08:44
Completely unhinged
dominiccummings
16/8/2023
08:25
Magpie . SHORT term 'out of pocket' magpie.
It's not as though WE ALL have not seen them come and go so many times before
The common theme is that they all think themselves soooo superior

the real lozan
16/8/2023
08:14
Nutter. Long term nutter.
dominiccummings
16/8/2023
08:10
" deleted it!"
GUFFAW
There must have been a number of 'wry smiles' that the "he comes from landan" invoked
Just like the infantile 'MINTED' one, 'Marcus my words' makes stuff up, to the point of having to 'deleted it!'.. it being known by many as being FACTUALLY INCORRECT
More 'balanced' observers may opine,that the trHYPISTS are showing signs of their frustration as the 'riches' CON tinue to FAIL to materialise.

the real lozan
16/8/2023
07:38
Marcus,Well it was until you deleted it!
ruckrover
15/8/2023
23:56
Marcus,That is the most interesting post you have made to date - thanks.
ruckrover
15/8/2023
22:35
Avidimab

SEA-CD40 (Seagen) is in Phase II trials for advanced solid tumours. AvidiMab was used in the Fc region (Exhibit 5) in an IgG1 format

iScib

Covidity

Ultraspecific SSEA4 mAb – lead AvidiMab® modified clinical candidate

marcusl2
15/8/2023
19:01
The bore at #5431 never went away of course.
dominiccummings
15/8/2023
14:24
As Lizzy used to say -
'The bores are back in town'

the real lozan
15/8/2023
08:02
Fascinating article Marcus, some parts over the top of my head, but I understand the picture.
SCLP, seems to be coming to boiling point.

rogerbridge
14/8/2023
15:31
Neoadjuvant therapies are delivered before the main treatment, to help reduce the size of a tumour or kill cancer cells that have spread. Adjuvant therapies are delivered after the primary treatment, to destroy remaining cancer cells.


31 July 2023
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that the ModiFY trial is now open for expansion in combination with checkpoint inhibitors (CPI) and in the neoadjuvant setting.

So looking forward to further Modi-1 data this year.

Scib-1 with doublet data
Transition to iScib

Antibodies, new 6-month evaluation by a leading Biotech company

Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company.

First deal/s for Avidimab

There was interest in SC2811
iSC2811 enhances T cell engraftment and prevents exhaustion
Potential for improving CAR-T approaches

News on SC129 mAb licensed to Genmab.

Updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023.


Modi-2 news.

marcusl2
14/8/2023
12:22
What do cancer-specific T cells ‘see’?
Sabaria Shah, Abdullah Al-Omari, Katherine W Cook, Samantha J Paston, Lindy G Durrant, Victoria A Brentville


Scancell
@scancellpharma
·
1h
Delighted our review article "What do cancer-specific T cells 'see'?", published in
@discovimmunol
, has been selected for inclusion in the 'High Impact Collection', highlighting research and reviews from across the BDI portfolio of journals.

marcusl2
14/8/2023
09:55
The 'Magpies' of the SCLP forums -
When Magpies move-in to an area where a variety of diverse wildlife co-exists, the Magpies WILL always take over and eliminate all forms of life..harass, bully, kill, dive-off all other wildlife..Claiming the area as their own..leaving an area barren.
This translates to these forums, where,as WE ALL see, the trHYPE family of Magpies have turned all interested parties away from voicing opinions/observations.
Dis-interest seems to extend beyond these forums to markets in general.
Should WE ALL be surprised ???

the real lozan
11/8/2023
18:26
MT, I assume when you say you own a big chunk of Scancell you are obviously talking about a certain % of the Company. I call that absolute BS. As for your colleague, have they been involved in any medical experiments in the last couple of years, a lot of Turbo Cancers out there, check out SV40.
panama7
11/8/2023
17:19
Sorry to hear that MT.
ruckrover
11/8/2023
13:14
I discovered this week that a relative of my IFA (who knows perfectly well that I hold a big chunk of Scancell) just died of neck cancer.I had to bite my tongue.
markingtime
11/8/2023
13:04
Yes Modi-2 for Prostate

Modi-2 targeting breast, colorectal, non-small
cell lung and prostate cancer

Modi-2
► Four homocitrullinated peptides from:
► Aldolase A
► Immunoglobulin binding protein (BiP)
► Cytokeratin 8
► Vimentin


Modi-2 SNAPvax™ particles mediate tumour therapy
► Balb/c mice injected with 4T1 tumour cells
► Tumours allowed to develop for 4 days
► Treated with Modi-2 SNAPvax™ mosaic particles or Modi-2
peptides mixed with CpG/MPLA adjuvant
► 70% of animals treated with Modi-2 SNAPvax™ particles survived

marcusl2
11/8/2023
12:27
bet you £200 that they will never use it for Prostate (iscib2) indeed trent uni and scancell have been playing for years with the Pap protein for prostate
inanaco
11/8/2023
12:03
Inan,No, I mean iSCIB2. Is Modi2 targeting prostate as well? Presumably both will have a role.
ruckrover
11/8/2023
10:32
you mean Modi2 ..
inanaco
11/8/2023
08:55
The world is mad!

Scancell mkt cap £119m

Moises Caicedo: Liverpool agree £111m fee

marcusl2
Chat Pages: Latest  2514  2513  2512  2511  2510  2509  2508  2507  2506  2505  2504  2503  Older

Your Recent History

Delayed Upgrade Clock